Rosuvastatin suppresses the liver microsomal CYP2C11 and CYP2C6 expression in male Wistar rats

Xenobiotica

Volumn 42, Issue 8, 2012, Pages 731-736

  Zachařová, Alice ^a   Šiller, Michal ^a   Špičáková, Alena ^a   Anzenbacherová, Eva ^a   Škottová, Nina ^a   Anzenbacher, Pavel ^a   Večeřa, Rostislav ^a  

^a PALACKÝ UNIVERSITY   (Czech Republic)

Author keywords

CYP2C6; Cytochrome P450 2C11; High cholesterol diet; Rat; Rosuvastatin

Indexed keywords

CYTOCHROME; CYTOCHROME P450 2C11; CYTOCHROME P450 2C6; ROSUVASTATIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CHOLESTEROL DIET; DRUG METABOLISM; ENZYME ACTIVITY; MALE; NONHUMAN; PROTEIN EXPRESSION; RAT;

ANIMALS; ARYL HYDROCARBON HYDROXYLASES; DIET, HIGH-FAT; FLUOROBENZENES; GENE EXPRESSION REGULATION, ENZYMOLOGIC; LIPIDS; MALE; MICROSOMES, LIVER; PYRIMIDINES; RATS; RATS, WISTAR; STEROID 16-ALPHA-HYDROXYLASE; STEROID 21-HYDROXYLASE; SULFONAMIDES;

RATTUS; RATTUS NORVEGICUS;

EID: 84863644762     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498254.2012.661099     Document Type: Article

References (29)

1. Ansari JA, Bhandari U, Haque SE, Pillai KK. (2012). Enhancement of antioxidant defense mechanism by pitavastatin and rosuvastatin on obesity-induced oxidative stress in Wistar rats. Toxicol Mech Methods 22:67-73.
2. Barbosa-Sicard E, Markovic M, Honeck H, Christ B, Muller DN, Schunck WH. (2005). Eicosapentaenoic acid metabolism by cytochrome P450 enzymes of the CYP2C subfamily. Biochem Biophys Res Commun 329:1275-1281. (Pubitemid 40568707)
3. Daniel WA, Haduch A, Syrek M, Boksa J. (2006). Direct and indirect interactions between antidepressant drugs and CYP2C6 in the rat liver during long-term treatment. Eur Neuropsychopharmacol 16:580-587. (Pubitemid 44716661)
4. Delsing DJ, Post SM, Groenendijk M, Solaas K, van der Boom H, van Duyvenvoorde W, de Wit EC, Bloks VW, Kuipers F, Havekes LM, Princen HM. (2005). Rosuvastatin reduces plasma lipids by inhibiting VLDL production and enhancing hepatobiliary lipid excretion in ApoE*3-leiden mice. J Cardiovasc Pharmacol 45:53-60. (Pubitemid 40039756)
5. Fassini PG, Noda RW, Ferreira ES, Silva MA, Neves VA, Demonte A. (2011). Soybean glycinin improves HDL-C and suppresses the effects of rosuvastatin on hypercholesterolemic rats. Lipids Health Dis 10:165.
6. Finsterer J, Stöllberger C. (2005). Myalgia, hyper-CK-aemia, and hypocoagulability in a patient under rosuvastatin and warfarin. Eur J Neurol 12:660. (Pubitemid 41117293)
7. Galani V, Vyas M. (2010). In vivo and In vitro drug interactions study of Glimepride with Atorvastatin and Rosuvastatin. J Young Pharm 2:196-200.
8. Gallelli L, Ferraro M, Spagnuolo V, Rende P, Mauro GF, De Sarro G. (2009). Rosuvastatin-induced rhabdomyolysis probably via CYP2C9 saturation. Drug Metabol Drug Interact 24:83-87.
9. Guengerich FP, Dannan GA, Wright ST, Martin MV, Kaminsky LS. (1982). Purification and characterization of liver microsomal cytochromes p-450: electrophoretic, spectral, catalytic, and immunochemical properties and inducibility of eight isozymes isolated from rats treated with phenobarbital or betanaphthoflavone. Biochemistry 21:6019-6030. (Pubitemid 13184201)
10. Havel RJ, Eder HA, Bragdon JH. (1955). The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest 34:1345-1353.
11. Ishizuka M, Okajima F, Tanikawa T, Min H, Tanaka KD, Sakamoto KQ, Fujita S. (2007). Elevated warfarin metabolism in warfarinresistant roof rats (Rattus rattus) in Tokyo. Drug Metab Dispos 35:62-66. (Pubitemid 46036477)
12. Jindal D, Tandon M, Sharma S, Pillai KK. (2005). Pharmacodynamic evaluation of warfarin and rosuvastatin co-administration in healthy subjects. Eur J Clin Pharmacol 61:621-625.
13. Kostapanos MS, Milionis HJ, Elisaf MS. (2010). Rosuvastatinassociated adverse effects and drug-drug interactions in the clinical setting of dyslipidemia. Am J Cardiovasc Drugs 10:11-28.
14. Lake BG. Preparation and characterization of microsomal fractions for studies on xenobiotic metabolism. (1990). In: Snell EK, Mullock B. Biochemical toxicology and practical approach. Oxford-Washington DC: IRL Press, 183.
15. Locatelli I, Kmetec V, Mrhar A, Grabnar I. (2005). Determination of warfarin enantiomers and hydroxylated metabolites in human blood plasma by liquid chromatography with achiral and chiral separation. J Chromatogr B Analyt Technol Biomed Life Sci 818:191-198. (Pubitemid 40331823)
16. McTaggart F, Buckett L, Davidson R, Holdgate G, McCormick A, Schneck D, Smith G, Warwick M. (2001). Preclinical and clinical pharmacology of Rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Am J Cardiol 87:28B-32B. (Pubitemid 32274242)
17. Mo SL, Zhou ZW, Yang LP, Wei MQ, Zhou SF. (2009). New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I. Curr Drug Metab 10:1075-1126.
18. Neuvonen PJ. (2010). Drug interactions with HMG-CoA reductase inhibitors (statins): the importance of CYP enzymes, transporters and pharmacogenetics. Curr Opin Investig Drugs 11:323-332.
19. Nezasa K, Takao A, Kimura K, Takaichi M, Inazawa K, Koike M. (2002). Pharmacokinetics and disposition of rosuvastatin, a new 3-hydroxy-3- methylglutaryl coenzyme A reductase inhibitor, in rat. Xenobiotica 32:715-727. (Pubitemid 34984968)
20. Orolin J, Vecera R, Markova I, Zacharova A, Anzenbacher P. (2009). Differences in hepatic expression of genes involved in lipid homeostasis between hereditary hypertriglyceridemic rats and healthy Wistar rats and in their response to dietary cholesterol. Food Chem Toxicol 47:2624-2630.
21. Pennisi G, Vacante M, Russo C, Malaguarnera M. (2010). Rhabdomyolysis induced by rosuvastatin and sildenafil. South Med J 103:1052-1054.
22. Reisin E, Ebenezer PJ, Liao J, Lee BS, Larroque M, Hu X, Aguilar EA, Morse SA, Francis J. (2009). Effect of the HMG-CoA reductase inhibitor rosuvastatin on early chronic kidney injury in obese zucker rats fed with an atherogenic diet. Am J Med Sci 338:301-309.
23. Rubba P, Marotta G, Gentile M. (2009). Efficacy and safety of rosuvastatin in the management of dyslipidemia. Vasc Health Risk Manag 5:343-352.
24. Simonson SG, Martin PD, Mitchell PD, Lasseter K, Gibson G, Schneck DW. (2005). Effect of rosuvastatin on warfarin pharmacodynamics and pharmacokinetics. J Clin Pharmacol 45:927-934. (Pubitemid 41060232)
25. Sugatani J, Sadamitsu S, Kurosawa M, Ikushiro S, Sakaki T, Ikari A, Miwa M. (2010). Nutritional status affects fluvastatin-induced hepatotoxicity and myopathy in rats. Drug Metab Dispos 38:1655-1664.
26. Vecera R, Skottová N, Vána P, Kazdová L, Chmela Z, Svagera Z, Walterá D, Ulrichová J, Simánek V. (2003). Antioxidant status, lipoprotein profile and liver lipids in rats fed on high-cholesterol diet containing currant oil rich in n-3 and n-6 polyunsaturated fatty acids. Physiol Res 52:177-187. (Pubitemid 36427820)
27. Vecera R, Zacharová A, Orolin J, Strojil J, Skottová N, Anzenbacher P. (2011). Fenofibrate-induced decrease of expression of CYP2C11 and CYP2C6 in rat. Biopharm Drug Dispos 32:482-487.
28. Wang H, Cheng JD, Montgomery D, Cheng KC. (2009). Evaluation of the binding orientations of testosterone in the active site of homology models for CYP2C11 and CYP2C13. Biochem Pharmacol 78:406-413.
29. Yamazaki H, Shimada T. (1997). Human liver cytochrome P450 enzymes involved in the 7-hydroxylation of R-and S-warfarin enantiomers. Biochem Pharmacol 54:1195-1203. Full Prescribing Information www.crestor.com. Accessed on 1 December 2011.